{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-145019","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.686781+00:00","generated_at":"2026-06-15T01:41:03.498470+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TherapeuticsMD Q1 net loss narrows to $2.3M from $17.9M; continuing ops loss $0.24/share","bullets":["Net loss from continuing operations $2.3M ($0.24/share) vs $17.9M ($2.08) in Q1 2022.","License and service revenues $0.4M, down from $0.7M due to transition to royalty-based business.","Total operating expenses fell 82.8% to $3.1M, reflecting business transformation and reduced infrastructure.","Net loss from discontinued ops $1.3M ($0.13/share) vs $31.1M ($3.62), as wind-down continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-145019","json":"https://secwatch.observer/filing/0001193125-23-145019.json","markdown":"https://secwatch.observer/filing/0001193125-23-145019.md","text":"https://secwatch.observer/filing/0001193125-23-145019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312523145019/0001193125-23-145019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312523145019/d481253d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:41:03.498470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9bf6cdefeedcf7a841901c6aa58503b93f7234b3","claim":"TherapeuticsMD, Inc. reported first quarter ended March 31, 2023 results: revenue $0.4 million, net income $2.3 million, EPS $0.24 per basic and diluted common share.","evidence_excerpt":"Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations of $17.9 million, or $2.08 per basic and diluted common share, for the comparable period in 2022. License and Service Revenues from Continuing Operations • License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended March 31, 2023, compared to $0.7 million in license and service revenue related to sales to other licensees for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312523145019/0001193125-23-145019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$0.4 million"},{"label":"Net income","value":"$2.3 million"},{"label":"EPS","value":"$0.24 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}